These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 22083586)

  • 1. Small molecule immunomodulatory drugs: challenges and approaches for balancing efficacy with toxicity.
    Haley PJ
    Toxicol Pathol; 2012; 40(2):261-6. PubMed ID: 22083586
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Safety and nutritional assessment of GM plants and derived food and feed: the role of animal feeding trials.
    EFSA GMO Panel Working Group on Animal Feeding Trials
    Food Chem Toxicol; 2008 Mar; 46 Suppl 1():S2-70. PubMed ID: 18328408
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Development of antituberculous drugs: current status and future prospects].
    Tomioka H; Namba K
    Kekkaku; 2006 Dec; 81(12):753-74. PubMed ID: 17240921
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Safety assessment and dose selection for first-in-human clinical trials with immunomodulatory monoclonal antibodies.
    Muller PY; Brennan FR
    Clin Pharmacol Ther; 2009 Mar; 85(3):247-58. PubMed ID: 19177065
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Anticancer Drug Development: The Way Forward.
    Connors T
    Oncologist; 1996; 1(3):180-181. PubMed ID: 10387985
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Alternative strategies for toxicity testing of species-specific biopharmaceuticals.
    Bussiere JL; Martin P; Horner M; Couch J; Flaherty M; Andrews L; Beyer J; Horvath C
    Int J Toxicol; 2009; 28(3):230-53. PubMed ID: 19546261
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Genotoxicity of 1,3-butadiene and its epoxy intermediates.
    Walker VE; Walker DM; Meng Q; McDonald JD; Scott BR; Seilkop SK; Claffey DJ; Upton PB; Powley MW; Swenberg JA; Henderson RF;
    Res Rep Health Eff Inst; 2009 Aug; (144):3-79. PubMed ID: 20017413
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Immunotoxicant screening and prioritization in the twenty-first century.
    Luebke R
    Toxicol Pathol; 2012; 40(2):294-9. PubMed ID: 22105646
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Overview of the nonclinical quality and toxicology testing for recombinant biopharmaceuticals produced in mammalian cells.
    Lebrec H; Narayanan P; Nims R
    J Appl Toxicol; 2010 Jul; 30(5):387-96. PubMed ID: 20589744
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Optimized nonclinical safety assessment strategies supporting clinical development of therapeutic monoclonal antibodies targeting inflammatory diseases.
    Brennan FR; Cauvin A; Tibbitts J; Wolfreys A
    Drug Dev Res; 2014 May; 75(3):115-61. PubMed ID: 24782266
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Species selection considerations for preclinical toxicology studies for biotherapeutics.
    Bussiere JL
    Expert Opin Drug Metab Toxicol; 2008 Jul; 4(7):871-7. PubMed ID: 18624676
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Relation of preclinical toxicology to findings in early clinical trials.
    Grieshaber CK; Marsoni S
    Cancer Treat Rep; 1986 Jan; 70(1):65-72. PubMed ID: 3943115
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Preclinical efficacy and safety models for mAbs: the challenge of developing effective model systems.
    Dixit R; Coats S
    IDrugs; 2009 Feb; 12(2):103-8. PubMed ID: 19204884
    [TBL] [Abstract][Full Text] [Related]  

  • 14. In vitro assays supporting the safety assessment of immunomodulatory monoclonal antibodies.
    Brennan FR; Kiessling A
    Toxicol In Vitro; 2017 Dec; 45(Pt 3):296-308. PubMed ID: 28263892
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Developmental toxicity testing of biopharmaceuticals in nonhuman primates: previous experience and future directions.
    Martin PL; Weinbauer GF
    Int J Toxicol; 2010 Dec; 29(6):552-68. PubMed ID: 20926830
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immunostimulatory antibodies: challenging the drug testing paradigm.
    Bhogal N; Combes R
    Toxicol In Vitro; 2007 Oct; 21(7):1227-32. PubMed ID: 17434714
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Future of toxicology--low-dose toxicology and risk--benefit analysis.
    Rietjens IM; Alink GM
    Chem Res Toxicol; 2006 Aug; 19(8):977-81. PubMed ID: 16918235
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Considerations regarding nonhuman primate use in safety assessment of biopharmaceuticals.
    Buckley LA; Chapman K; Burns-Naas LA; Todd MD; Martin PL; Lansita JA
    Int J Toxicol; 2011 Oct; 30(5):583-90. PubMed ID: 22013138
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Antiretroviral drug studies in nonhuman primates: a valid animal model for innovative drug efficacy and pathogenesis experiments.
    Van Rompay KK
    AIDS Rev; 2005; 7(2):67-83. PubMed ID: 16092501
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Immunotoxicity testing in nonhuman primates.
    Grote-Wessels S; Frings W; Smith CA; Weinbauer GF
    Methods Mol Biol; 2010; 598():341-59. PubMed ID: 19967524
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.